AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Tablets, Oral, 500-2500 mg, as needed (12 months LT)
Study NCT00295633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2500 mg, as needed (12 months LT)
Study NCT00520455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms
Description: levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
Study NCT01956149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
Study NCT01043679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utapine
Description: Efficacy and Safety of Utapine
Study NCT01043679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: Efficacy and Safety of Seroquel
Study NCT02248259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Oral single dose of BI 409306
Study NCT02248259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
Study NCT03486886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA -PET/CT scanning
Description: PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis).
Study NCT01809132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
Study NCT01809132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline, generic
Study NCT01809132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc Sulfate, nutritional supplement
Study NCT01809132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone, corticosteroid
Study NCT01582542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured.
Study NCT03312348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared imaging
Description: Infrared image image acquisition of study participants
Study NCT01958723 — intervention group
Intervention type: OTHER
Intervention: Hospitalists
Description: Introduction of Problem Specific Templates
Study NCT04466644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Antibody test (serology) in the blood samples to determine if the subject was previously infected.
Study NCT04466644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: For detecting the presence of SARS-CoV-2 RNA molecule in the nasopharyngeal swabs and saliva.
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT03226418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study NCT03226418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03226418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by infusion
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral tablet
Study NCT03226418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glasdegib
Description: oral tablet
Study NCT03457545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
Study NCT03457545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aidcube
Description: Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
Study NCT02357134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive high-flow oxygen
Study NCT02357134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive high-flow air
Study NCT02357134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02357134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02357134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02357134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02357134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Therapy
Description: Receive low-flow oxygen
Study NCT02357134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Therapy
Description: Receive low-flow air
Study NCT04055181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS in schizophrenia Controls
Description: all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
Study NCT04055181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS in schizophrenia patients
Description: 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
Study NCT04055181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS in major depressive disorders controls
Description: all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
Study NCT04055181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS in major depressive disorders patients
Description: 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
Study NCT03305939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style Intervention
Description: The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~1. simple healthy eating and moderate physical activity messages;~2. behavioral skills such as problem solving/goal setting/self-monitoring; and~3. enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context.
Study NCT02163460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain
Description: In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde \[Health Ministry registry\]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
Study NCT02163460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Tension Sutures
Description: Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
Study NCT04032691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Pill
Description: 0.1 mg by mouth daily at bedtime for one week
Study NCT02668653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00462995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg once a day for 28 days
Study NCT00462995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
Study NCT02048670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Belt
Description: Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
Study NCT02048670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance Belt
Description: Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
Study NCT00722072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
Study NCT00722072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
Study NCT03583450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perioperative virtual reality headset with mobile app
Description: Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
Study NCT04621734 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMT BridlePro Device
Description: A device used as an alternative securement method using the structure of the nasal cavity to secure the nasoenteric tube.
Study NCT04621734 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Adhesive Tape
Description: Adhesive tape used to secure nasoenteric tube
Study NCT03177616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Treatment
Description: The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~* posture correction/spinal stabilization exercises~* soft tissue relaxation techniques~* spinal manipulation (i.e. chiropractic adjustment)/mobilization~* breathing and relaxing techniques~* stretches, self-care~* ergonomic modifications~* bracing and supports
Study NCT03502239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mega Team - video game
Description: Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
Study NCT01440868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained lung inflation
Description: Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher \& Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR \<100 bpm ).
Study NCT01031550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoflurane
Description: isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
Study NCT01031550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: standard of care
Study NCT01297764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Description: Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~1. 15 15 300 40~2. 20 15 300 40~3. 20 25 300 40~4. 20/27\* 25 300 40~5. 20/27\* 25 400 40
Study NCT04546568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - Leoni plus CLAC
Description: FiO2 adjustments will be made by the Leoni plus CLAC (Closed-Loop Automated oxygen Control) ventilator (Leoni plus, Löwenstein Medical, Germany).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.
Study NCT04546568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Servo control (closed-loop automatic control of the inspiratory fraction of oxygen (FiO2)) - IntellO2 OAM
Description: FiO2 adjustments will be made by the IntellO2 Oxygen Assist Module (OAM) for Precision Flow (IntellO2, Vapotherm, USA).~Manual adjustments of the inspired oxygen fraction can additionally be made as per standard care.
Study NCT01957995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanosomal docetaxel lipid suspension
Description: Given IV
Study NCT01957995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00067002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded allogeneic cord blood (CB)
Description: Transplantation of Two Unmanipulated Cord Blood Units.
Study NCT00067002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Unmanipulated and One Expanded Cord Blood Unit
Description: Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
Study NCT00067002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: 375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
Study NCT00610545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Study NCT00610545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
Study NCT03858790 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PINS Spinal Cord Stimulator
Description: Subjects will be implanted with PINS spinal cord stimulator
Study NCT03858790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINS Spinal Cord Stimulator
Description: Subjects will be implanted with PINS spinal cord stimulator
Study NCT00467779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobimetinib
Description: Repeating oral dose
Study NCT00067002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2 by vein on Day -8.
Study NCT00067002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/Kg by vein on Day -7.
Study NCT00067002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2 by vein on Days -6 to -3.
Study NCT00067002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg by vein on Day -6.
Study NCT00067002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
Study NCT00067002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Total body irradiation (TBI) given on Day -1 at 2 Gy.
Study NCT03315663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App & DBWS
Description: Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
Study NCT03315663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweetch App Alone
Description: Usual care for prediabetes management, Sweetch app alone.
Study NCT01099176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: To compare monotherapies and combined therapy with each other
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets
Study NCT01099176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: To compare monotherapies and combined therapy with each other
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets
Study NCT04580979 — intervention group
Intervention type: GENETIC
Intervention: Mutation analysis
Description: The investigators will sequence DNA samples from the patients or their families.
Study NCT00843700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Trauma in Community Settings
Description: Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
Study NCT00843700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individual psychotherapy following usual care practice in a community mental health center.
Study NCT00467779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan
Description: In Stage III only: single dose of dextromethorphan
Study NCT00467779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: In Stage III only: single dose of midazolam
Study NCT06149390 — intervention group
Intervention type: DRUG
Intervention: consolidation with ASCT
Description: high dose chemotherapy （BCNU, etoposide, cytarabine and melphalan)）and auto stem cells transfusion
Study NCT03632109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin 360mg IM
Description: 360mg IM of gentamicin
Study NCT01444014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: 50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
Study NCT00437385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCAs, SSRIs, NARIs, SNRIs, Lithium
Description: Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)